drugset / Trial / NCT07034391

A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

NCT07034391

Phase 2 Recruiting 40 enrolled China Medical University, China
NaSingle-groupOpen-labelTreatment

Summary

This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1/PD-L1 inhibitor in locally advanced or metastatic NSCLC.

Timeline

Start
2025-05-12
Primary completion
2026-10-31
Completion
2027-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject Denosumab Monoclonal antibody 120 mg
Subject Pemetrexed Small molecule 500 mg/m2